The flexibility of CCSG Development funds provides the Director with the ability to support evolving opportunities that support the goals established by the leaders of UWCCC. There are three areas where Development Funds play a critical role: start-up support for new faculty;pilot project research funding and the development of new Shared Resources. The Director commits CCSG development funds for start-up support for faculty candidates who provide the most promising opportunities for significant contributions to the Scientific Programs of UWCCC. During the current grant period, UWCCC contributed $2.5 million towards the recruitment of 28 tenure track faculty. These faculty have been awarded approximately $43.4 million in grant funding for a 17 fold return on investment to date. In concert with the priorities established for future development, candidates will be chosen because of their promising potential to conduct laboratory cancer research leading to translation, or to contribute to applied research resulting from translation. Pilot projects are an important mechanism to support early explorations leading to research that will fulfill the discovery through translation mission of UWCCC. A coordinated process, similar to an NIH study section, ensures that the resources of UWCCC are used effectively. The process has evolved to align the goal of strengthening cancer-focused collaborative projects that include intra- and trans-disciplinary laboratory and clinical research with translational end-points. During the current grant period. UWCCC funded 85 pilots with $4 million which have generated approximately $23 million in grant awards and 66 publications to date. Shared Resources are one of the most important mechanisms that UWCCC uses to encourage investigators to take advantage of opportunities for collaboration and focus their research on cancer. Scientific opportunity is a powerful enticement, but when it is paired with fiscal benefit, the opportunity is magnified. We will allocate resources for new Shared Resources that will have a significant impact on the translational potential of our research efforts and support areas targeted for future development. Future Shared Resource development in the next grant period will focus on informatics and genomics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-39
Application #
8483776
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2018-03-31
Budget Start
2013-04-12
Budget End
2014-03-31
Support Year
39
Fiscal Year
2013
Total Cost
$446,768
Indirect Cost
$66,047
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70
Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24
Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31
Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17
Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607
Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609
Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8
LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76
Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9
Nihal, Minakshi; Ahmad, Nihal; Wood, Gary S (2014) SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 13:632-40

Showing the most recent 10 out of 472 publications